Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Guanine-Cytosine (GC)-rich DNA promoter motifs are critical regulatory elements located within the proximal promoter regions of approximately 60-70% of mammalian genes, including many essential housekeeping genes and potent oncogenes [1]. These motifs, often referred to as GC boxes, typically serve as high-affinity binding sites for the Sp1 (Specificity Protein 1) family of transcription factors, which orchestrate the recruitment of the basal transcription machinery to initiate gene expression [2]. In various malignancies, the aberrant activation of genes controlled by GC-rich promoters—such as c-Myc, VEGF, and BCL2—drives tumor progression, angiogenesis, and resistance to apoptosis [2]. Therapeutic strategies targeting these motifs involve small-molecule ligands, such as Mithramycin A and its derivatives, which bind to the DNA minor groove to competitively inhibit transcription factor binding [3, 4]. While effective at downregulating pathogenic genes, the ubiquitous nature of GC-rich sequences across the genome presents significant challenges regarding off-target effects and systemic toxicity, necessitating the development of more selective analogs [4, 5]. Sources: [1] Suske G. Gene. 1999;238(2):291-300. [2] Vizcaíno C, et al. J Hematol Oncol. 2015;8:8. [3] Miller DM, et al. Cancer. 1987;60(11):2604-2611. [4] Albertini V, et al. Med Res Rev. 2010;30(2):310-341. [5] NIH PubChem Compound Summary for Mithramycin A.
Small molecule ligands bind to the minor groove of GC-rich DNA sequences, physically displacing transcription factors such as Sp1 and preventing the assembly of the transcription initiation complex, thereby inhibiting the expression of downstream genes [3, 4].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Guanine-Cytosine-rich DNA promoter motifs (GC-rich motifs).